We show here that systemic delivery of an albumin-hitchhiking siRNA–lipid conjugate targeting MMP13 achieves robust delivery, MMP13 silencing and therapeutic efficacy in joints afflicted by OA and RA. Here, MMP13 is linked to rheumatoid arthritis.